SurModics (SRDX) Tops Q1 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
SurModics Reports First Quarter Fiscal 2016 Results
January 28, 2016 7:35 AM ESTGAAP Revenue of $16.5 Million, up 16% GAAP EPS of $0.19, Non-GAAP EPS of $0.38 Fiscal 2016 Guidance Reaffirmed
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- SurModics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2016 first quarter, ended December 31, 2015.
The SurModics team had an exceptional first quarter of fiscal 2016, said Gary Maharaj, president and chief executive officer. We delivered outstanding results from our core Medical Device and In Vitro Diagnostic... More
